Journal

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Adrián Llerena

Language: English

First published: December 1, 1980

View latest issue

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

About this journal

Objective

Drug Metabolism and Personalized Therapy (DMPT) is the official journal of the European Society of Pharmacogenomics and Personalised Therapy (ESPT). DMPT offers up-to-date research articles, reviews and opinion papers from the broad field of personalized therapy and pharmacogenomics. Specifically, it covers the following fields: pharmacogenetics, pharmacogenomics and drug metabolism research, dealing with established, new and potential drugs, herbal medicinal products, environmentally toxic chemicals, the mechanisms by which drugs and herbs can interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions, as well as drug metabolism and excretion. More generally, it is concerned with the area of therapeutic individualization, particularly on the basis of pharmacogenetics, with regards to the use of pharmaceuticals and herbal medicine, including traditional medicine.
DMPT is an international scientific single-blind peer-review journal, which is issued quarterly with 8-10 articles per issue. The Journal publishes only English-language articles.

Please submit your manuscript here

Topics

drug metabolizing enzymes
pharmacogenetics and pharmacogenomics
biochemical pharmacology
molecular pathology
clinical pharmacology
pharmacokinetics and drug-drug interactions
immunopharmacology
neuropsychopharmacology
herbal medicine and traditional medicine

Article formats
Research Articles, Reviews and Mini Reviews, Opinion Papers, Short Communications, letters to the Editor, Case Reports, Editorials

Your Benefits

Your benefits:

Comprehensive approach to drug metabolism research
State-of-the-art research results
Renowned editorial board
High quality peer-review

Requires Authentication Unlicensed
Licensed

Exploring two medicinally important Selinum species: bridging traditional knowledge with modern pharmacological insights

December 17, 2025

Ruchika Kumari, Palak Thakur, Vipasha Sharma, Ashun Chaudhary

Download PDF

Background Selinum is an important genus in the Apiaceae family, known for its essential oil-bearing medicinal properties. Selinum vaginatum C. B. Clarke and Ligusticopsis wallichiana (DC.) Pimenov & Kljuykov (Syn. Selinum wallichianum (DC.) Raizada & H. O. Saxena and Selinum tenuifolium Wall. ex DC.) are the two important species found in Himachal Pradesh, India. Content The primary objective of this review is to present an updated report on the phytochemistry, traditional knowledge, and pharmacological profile of two species of the genus Selinum that are found in the Western Himalayas. Summary The genus Selinum is commonly referred to as Bhutakeshi or Bhootkeshi. Strong evidence supports Selinum ’s claims for its traditional ethnomedical importance and is used to treat cardiovascular diseases, asthma, toothache, mental disorders and diabetes. It is also used as an insect repellent and in magico-religious practices. The plant has antioxidant, anti-inflammatory, anticancer, anticonvulsant, and antimicrobial activities. The plant is rich in phenols, flavonoids, alkaloids, and terpenoids that contribute to its bioactivities. Outlook This review outlines the important phytochemicals, traditional uses, and potential pharmacological properties of Selinum species. Further investigation is needed to elucidate the mechanistic importance of its bioactive components in drug development processes and to investigate the therapeutic potential at the clinical level.
Requires Authentication Unlicensed
Licensed

Neural network modelling of experimental diabetes to study new antidiabetic drugs

November 18, 2025

Zhansulu Nurgaliyeva, Ayazhan Dauletkaliyeva, Serzhan Dauletkaliyev, Dana Tolegen, Rauza Romanova

Download PDF

Objectives Diabetes mellitus is a complex metabolic disease characterised by chronic hyperglycaemia, which triggers a cascade of pathological changes in the body. Contemporary methods for developing antidiabetic drugs are often lengthy, expensive, and not always effective. The use of neural networks for modelling diabetes opens up new possibilities for accelerating research and increasing the accuracy of predicting the effectiveness of novel therapeutic strategies. The aim of this study was to develop and validate a neural network for studying experimental diabetes and assessing the efficacy of new antidiabetic drugs, as well as to explore the potential of combined therapeutic strategies. Methods The empirical investigation was conducted using laboratory models of diabetes induced in rats with streptozotocin. Three groups were formed: a control group, a diabetic group without treatment, and a diabetic group treated with experimental drugs. Results A neural network, based on multilayer perceptrons and recurrent architectures, was trained to predict changes in glucose levels, oxidative stress markers, and the condition of pancreatic tissues. The developed model demonstrated high predictive accuracy of metabolic changes, with an average accuracy of 92.3 %. As a result of treatment with experimental drugs, blood glucose levels in rats decreased by 25–30 % over 28 days, accompanied by a 26 % reduction in oxidative stress markers and partial restoration of pancreatic β-cell function in 30 % of cases. Histological analysis confirmed reduced fibrosis and improved tissue condition in the treatment group. The model also identified that combined therapeutic strategies – for example, the combination of antioxidants with gluconeogenesis inhibitors – had a synergistic effect, lowering glucose levels by up to 40 %. Conclusions The study confirmed the effectiveness of the developed neural network for analysing therapeutic strategies and predicting metabolic changes in diabetes models. The proposed neural network represents a promising tool for investigating new antidiabetic drugs, including efficacy assessment within personalised medicine. Its application may accelerate preclinical research, optimise therapeutic approaches, and contribute to reducing drug development costs.
Requires Authentication Unlicensed
Licensed

The lack of ESR1 ethnic diversity evidence and its implications for breast cancer personalized treatment

November 18, 2025

Caíque Manóchio, Henrique Faleiros, Jessica F. Vieira, Arthur Oliveira-Ferreira, Rosekeila S. Nomelini, Fernanda Rodrigues-Soares

Download PDF

The ESR1 gene encodes estrogen receptor alpha (ERα), whose central role in breast tumorigenesis has supported the development of endocrine therapies, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Despite their proven efficacy, resistance, relapse, and treatment-limiting toxicity remain frequent, underscoring interindividual and interpopulation variability in therapeutic outcomes. Allelic diversity within ESR1 is a key determinant of these differences, as variant frequencies and distributions vary substantially across populations and ethnic groups. Associating ESR1 variants with genomic ancestry can help anticipate variability in drug response, thereby reducing adverse events and facilitating the clinical implementation of pharmacogenetics. Investigating population-specific differences that shape drug efficacy and toxicity not only generates evidence for groups historically underrepresented in genomic studies but also enhances the equity and global applicability of personalized medicine. In conclusion, genetic variation in ESR1 may modulate both the efficacy and safety of breast cancer therapies. Understanding the genetic diversity of populations worldwide is therefore essential for minimizing adverse effects, improving treatment outcomes, and advancing the implementation of pharmacogenetics in clinical practice.
Requires Authentication Unlicensed
Licensed

Evaluation of antimicrobial and immunomodulatory activities of Eugenol isolated from Syzygium aromaticum in a rat model

November 20, 2025

Raghad Abdulsalam Khaleel, Zinah Essam Hameed, Omar Hussein Ahmed

Download PDF

Objectives The increasing resistance of human infections to pharmaceutical treatments represents a critical global health challenge. Traditional herbs may complement modern antibacterial strategies. This study investigates the antimicrobial, antioxidant, and immunomodulatory properties of Eugenol extracted from Syzygium aromaticum . Methods The essential oil was achieved through hydro distillation and analyzed using HPLC. Antioxidant capabilities were assessed using the DPPH radical scavenging assay and reducing power. MTT assays revealed the viability percentages of A549 and MRC5 cell lines after 48 h of exposure to methanolic extract and valerianic acid. Minimum inhibitory concentration (MIC) and broth microdilution methods were utilized to test antibiotic activity against Staphylococcus aureus , Escherichia coli , and Candida albicans . Finally, the essential oil (average concentration 13.1 % ± 0.23, with major components Eugenol, β-caryophyllene, and Eugenol Acetate) was orally administered to rats for 14 days. In vivo safety and immunomodulatory effects were assessed through histopathological, hematological, and hepatic enzyme analyses, as well as cytokine profiling. Results The essential oil, rich in Eugenol, β-caryophyllene, and Eugenol acetate, demonstrated strong antioxidant activity. It exhibited significant antimicrobial effects at concentrations≥5 mg/mL, with inhibition zones comparable to standard antibiotics. Cytotoxicity remained low, and in vivo analysis revealed no adverse effects. The extract also increased IFN-γ and IL-4 levels, indicating immunomodulatory potential. Conclusions The study indicated an immunomodulatory impact by increasing IFN-γ and IL-4 levels, with no negative effects on hepatic enzymes, hematological parameters, or histopathology. In summary, this research demonstrates that Eugenol, even at low concentrations, exhibits promising antioxidant and antimicrobial activities against common pathogens.
Requires Authentication Unlicensed
Licensed

Assessing the attitude to pharmacogenomics testing among pharmacists in Iraq

November 19, 2025

Yazun Bashir Jarrar, Dina Abu Hashem, Mariam Homsi, Abdulqader Fadhil Abed, Yasmeen Ibrahim

Download PDF

Objectives Pharmacogenomics (PGx) testing optimizes drug efficacy and minimizes adverse effects, yet its implementation in Iraq remains limited. This study assessed Iraqi pharmacists’ attitudes toward PGx testing to identify gaps in education and clinical readiness. Methods A cross-sectional survey of 99 Iraqi pharmacists was conducted (June–August 2020). The 20-item questionnaire evaluated demographics, PGx education exposure, attitudes, and self-reported competence using a three-point Likert scale. Data were analyzed descriptively via SPSS. Results Most participants were young (83 % aged 21–30), held bachelor’s degrees (87.88 %), and supported PGx integration into curricula (80.81 %). While 95 % believed pharmacists should possess PGx knowledge, self-reported competency was low (35–54 %). Conclusions Despite strong support for PGx, limited educational exposure and low confidence in applying PGx testing highlight the need for curriculum enhancements and targeted training programs in Iraq. Iraqi pharmacists recognize PGx’s clinical value but require further education to bridge competence gaps. Policymakers should prioritize PGx training to facilitate implementation.
Requires Authentication Unlicensed
Licensed

Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases

November 20, 2025

Goitybell Martínez Téllez, Beatriz Marcheco Teruel

Download PDF

The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase ( MTHFR ) and solute carrier family 19 member 1 ( SLC19A1 ) genes involved in methotrexate pathways. Over the past decade, several functional polymorphisms affecting methylenetetrahydrofolate reductase activity have been studied in the context of low-dose methotrexate therapy. The most frequently investigated polymorphisms are rs1801133 (c.665C>T) and rs1801131 (c.1286A>C) in MTHFR gene and rs1051266 (c.80A>G) in SLC19A1 gene. Although the effects of these polymorphisms are remaining unclear, several studies have shown association with adverse effect while fewer studies have demonstrated association with remission or positive response to methotrexate. However, there is scarcity research in Latin American population assessing the influence of genetic variants in the pharmacokinetics and pharmacodynamics of methotrexate in the context of interethnic admixture. There is an urgent need of to expand these studies and to support the development of clinical pharmacogenomics guidelines.
Requires Authentication Unlicensed
Licensed

Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry

November 18, 2025

Carla González de la Cruz, Fernanda Rodrigues-Soares, Mariela Guevara, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena

Download PDF

Fluoropyrimidines are chemotherapy treatments widely used in chemotherapeutic regimens for different types of cancer. Adverse effects produced by dihydropyrimidine dehydrogenase (DPD) enzyme deficiency due to single nucleotide variants (SNVs) in the limiting enzyme of fluoropyrimidine catabolism occur with a high frequency in the world population; however, clinical recommendation guidelines focus mainly on variants of DPD gene ( DPYD ), which are highly prevalent in European populations. The aim of this review is to identify clinically relevant DPYD variants considering ethnic origin in order to develop population-specific genotyping panels for Afro-Latin Americans. Current recommendations from clinical guidelines and scientific literature in populations of African origin, including Dominican, have been reviewed. Based on the high reported frequency, the inclusion of the c.557A>G variant (which leads to a decrease in DPD enzyme activity) in populations of Afro-Latin American ancestry is proposed.
Open Access
Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats

October 2, 2024

Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair

Download PDF

Objectives Withania somnifera (WS) is a valuable medicinal plant that has been used against several ailments. The medicinal properties of WS are ascribed to existence of secondary metabolites which are in great demand in herbal nutraceutical industry. Despite well-known therapeutic effects of WS, it is necessary to assess preclinical toxicity of WS plant on rats and further explore its potential application against treatment of various disorders in humans. The existing study assessed oral acute and sub-chronic toxicities of WS root extract in Sprague Dawley (SD) rats (male and female) for 14 and 90 days, respectively under OECD-423 and -408 guidelines as well as GLP compliance. Methods In acute toxicity, rats of either sex were orally fed a dose of 2,000 mg/kg. In sub-chronic toxicity, animals were orally administered repeated doses of WS root extract at 250, 500, 1,000 mg/kg for 90 days with an additional 14-day recovery period. Two more groups (n=5 animals each) receiving vehicle and 1,000 mg/kg of WS root extract for 90 days were also observed. Results In acute toxicity, the results revealed that LD 50 of WS root extract in SD rats was higher than 2,000 mg/kg. In sub-chronic toxicity, oral administration of extract for 90 days showed no significant toxicological changes in rats. Haematological and serum chemistry markers were found within normal range. Terminal necropsy showed no gross or histopathological outcomes. Conclusions The no-observed-adverse-effect level (NOAEL) of WS root extract was 1,000 mg/kg body weight, and safe to use at this dose in rats.
Requires Authentication Unlicensed
Licensed

Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients

June 30, 2023

Natalia P. Denisenko, Anastasia A. Kachanova, Ivan V. Sychev, Gregory N. Shuev, Oksana M. Perfilieva, Reis H. Mukhamadiev, Ruslan E. Kazakov, Olga I. Milyutina, Olga V. Konenkova, Sergey A. Ryzhkin, Elena M. Zhmaeva, Sergey L. Kirienko, Dmitriy V. Ivashchenko, Irina V. Bure, Alexander S. Ametov, Irina V. Poddubnaya, Karin B. Mirzaev, Dmitry A. Sychev

Download PDF

Objectives Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients. Methods The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. NFKB1 , ATM , ATG16L2 , ATG10 , TGFB1 , and TNF polymorphisms were determined by allele-specific realtime-PCR. Results The frequency of adverse reactions was the following: gastrointestinal symptoms – 57.9 %, local symptoms – 65.8 %, cerebral symptoms – 46.8 %, fatigue – 54.4 %; signs of sialoadenitis six months after radioiodine therapy – 25.2 %. TT genotype carriers of ATG10 rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of ATG10 rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of TGFB1 rs1800469 (vs. AG+GG). CC genotype of ATG10 rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the ATM rs11212570 had a protective role against fatigue. TGFB1 rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy. Conclusions Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.
Open Access
Whole genome circRNA profiling of Withania somnifera in human neuroblastoma SK-N-SH cells

December 17, 2025

Anand Bhaskar, Dilip Mehta, Bhirisha Sharma, Jash Trivedi, Dhananya S, Manju Moorthy, Gopalakrishna Ramaswamy, Sujit Nair

Download PDF

Objectives Defined by their unique covalently closed loop, circular RNAs (circRNAs) are a specific class of noncoding RNAs known for their stability and resilience against degradation. They act as microRNA sponges, transcriptional regulators, and modulators of protein interactions. Withania somnifera (WS), a prominent member of the Solanaceae family, is renowned for its anti-oxidative and neuroprotective properties. Although circRNAs are recognized as critical regulators in neurological disorders, their putative roles in eliciting the health-beneficial effects of WS, also known as Ashwagandha, are still unexplored. Methods This study investigates WS-modulated global circRNA expression profiles in the SK-N-SH human neuroblastoma cell line, a widely used model for brain-related diseases. We conducted whole genome circRNA profiling using sequencing to identify differentially expressed circRNAs upon WS treatment. Results A total of 26,489 circRNAs were detected, out of which 1,515 were novel. Dose-dependent and temporal differential gene expression analysis found 26 upregulated and 20 downregulated circRNAs which were linked to pathways relevant to neuroinflammation, synaptic plasticity and neuronal survival through functional and pathway enrichment analysis. Conclusions This study sheds light on the regulatory roles of circRNAs in WS’s therapeutic effects, suggesting that modulating circRNA expression may be a key mechanism by which it exerts its benefits. These findings open new avenues for WS-based therapeutic strategies for brain-related diseases, thereby highlighting the therapeutic utility of circRNAs in neurological contexts.
Publicly Available
Relevance of personalized medicine for improving traditional medicine

August 24, 2023

Ingrid Fricke-Galindo, Adrián LLerena

Download PDF
Requires Authentication Unlicensed
Licensed

Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies

June 1, 2023

Kirti Raina, Ruchika Kumari, Palak Thakur, Rohit Sharma, Randeep Singh, Abhinay Thakur, Vikas Anand, Rohit Sharma, Ashun Chaudhary

Download PDF

Introduction Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues. Content The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study. Summary The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging. Outlook This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.
Publicly Available
PDE5 inhibitors: breaking new grounds in the treatment of COVID-19

August 24, 2023

Ryan Varghese, Gargi Digholkar, Jainam Karsiya, Sahil Salvi, Jeenam Shah, Dileep Kumar, Rohit Sharma

Download PDF

Introduction Despite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment. Content Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system. Repurposing and developing phosphodiesterase 5 (PDE5) inhibitors could extrapolate their utility to combat the SARS-CoV-2 infection, and potentially aid in the management of the symptoms associated with its newer variants such as BF.7, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16. Summary Administration of PDE5 inhibitors via the oral and intravenous route demonstrates other potential off-label benefits, including anti-apoptotic, anti-inflammatory, antioxidant, and immunomodulatory effects, by intercepting several pathways. These effects can not only be of clinical importance in mild-to-moderate, but also moderate-to-severe SARS-CoV-2 infections. This article explores the various mechanisms by which PDE5 inhibitors alleviates the symptoms associated with COVID-19 as well as well as highlights recent studies and findings. Outlook These benefits of PDE5 inhibitors make it a potential drug in the physicians’ armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events.
Requires Authentication Unlicensed
Licensed

Ancestromics

December 7, 2023

Ingrid Fricke-Galindo, Adrián LLerena

Download PDF
Requires Authentication Unlicensed
Licensed

Histomorphological study of hepatic lobules of adult Wistar rats administered with aqueous extracts of leaves of cassia singueana

March 20, 2023

Jemila Alley, Adam N. Jibril, Sagir M. Saleh, Mikail Umar, Mujittapha U. Sirajo

Download PDF

Objectives Cassia singueana is widely used in northern Nigeria as an herb for the treatment of enamors ailments. Nevertheless the toxicity of the herb on liver architecture; the hepatic lobule and body weight is yet to be authenticated. Methods A total of 24 male Wistar rats with an average weight of 150 g were randomly placed into four groups. Each group consisted of 6 rats. Group A served as the control group while groups B, C and D were given 150, 300, and 450 mg of Cassia singueana leaves extract respectively for 14 days. The animals were weighed before, during and after the treatment phase subsequently, they were sacrificed and the liver tissues were processed and stained using hematoxylin and eosin (H&E) stain, Masson’s and Trichrome Stain, Gordon and Sweet’s Stain, and Periodic Acid Schiff (PAS)Stain. Results There was no significant change in the animal’s body weight of in all the groups when compared to the control group. Our histology result showed that Cassia singueana induced vascular lesion and hepatocytes degeneration putatively though mechanism of cell death (apoptosis and necrosis). It was also found that Cassia singueana has no toxic effect on the reticular fibers of the liver. High dose of Cassia singueana was found to induce the deposition of PAS positive materials in hepatocytes. Conclusions The Cassia singueana leaves extract induce hepatocyte degeneration and vascular lesion in the hepatic lobules of the wistar rats, without affecting the animals’ body weight.
Requires Authentication Unlicensed
Licensed

Dr. José María Cantú Garza award

December 16, 2025

Ingrid Fricke-Galindo, Adrián LLerena

Download PDF

to be implemented...

Issue 0

Issue 40

Issue 39

Issue 38

Issue 37

Issue 36

Issue 35

Issue 34

Issue 33

Issue 32

Issue 31

Issue 30

Issue 29

Issue 28

Issue 27

Issue 26

Issue 25

Issue 24

Issue 23

Issue 22

Issue 21

Issue 20

Issue 19

Issue 18

Issue 16

Issue 17

Issue 15

Issue 14

Issue 13

Issue 12

Issue 11

Issue 10

Issue 9

Issue 8

Issue 7

Issue 6

Issue 5

Issue 4

Issue 3

CiteScore	2.4	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.271	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.32	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

More information about journal rankings

Submission
You can easily submit your manuscript online. Simply go to https://mc.manuscriptcentral.com/dmpt and you will be guided through the whole submission and publishing process.

Your benefits of publishing with us

Rapid publication times
No submission and publication fee
Optional Open Access Publication
Free color illustrations
Accepted papers will be published online first as DOI-citable, forward-linked articles for quickest possible visibility for the scientific community
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Submission process

Submission of your manuscript via our submission tool ScholarOne following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 2-4 weeks
Accepted articles are published online ahead of print approx. 4 weeks after acceptance

Please note

Manuscripts must be written in clear and concise English
Before submitting your article please have a look at the DMPT Submission Checklist, the Publication Ethics Statement and our copyright agreement
As a condition of submission, the Template for Ethical and Legal Declarations must be customized by the submitting author on behalf of all others and uploaded as a separate Word file. Instructions on how to make declarations can be found here
Once your article is accepted you have the option to publish it open access
Our repository policy allows you to distribute 30 PDF copies of your published article to colleagues (the PDF has to include the information that it is an author's copy). Please also feel free to distribute the link to the online abstract
Please also feel free to distribute the link to the online abstract If you have any general questions please visit our FAQ page for authors
For more detailed information please contact the DMPT Editorial Office DMPT.Editorial@degruyter.com

We look forward to receiving your manuscript!

Hybrid Open Access

In this journal, authors have the option to publish their article under an open access license. Open Access allows you as an author to retain copyright and share your findings with colleagues and interested parties worldwide without any restraints.
Please note that authors from institutions with which we have a transformative agreement can publish open access without paying an article processing charge (APC). More information on the eligible institutions and articles can be found　under the "Funding and Support" tab HERE.

Editor-in-Chief
Adrián LLerena
CICAB Clinical Research Center, Extremadura University Hospital, Badajoz, Spain
allerena@unex.es

Associate Editor
Vangelis G. Manolopoulos, Dept. of Pharmacology, Democritus University of Thrace Medical School, Alexandroupolis, Greece

Managing Editor
Ingrid Fricke-Galindo, Mexico City, Mexcio

Editorial Board
Mongi Benjeddou, Dept. of Biotechnology, University of the Western Cape, Cape Town, South Africa
Bing Chen, Shanghai, Dept. of Laboratory Medicine, Jiaotong University, Shanghai, P.R. China
Jorge Duconge, Medical Center, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Jaroslav Hubacek, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Magnus Ingelman-Sundberg, Dept. of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Giorgio D. Kotzalidis, Dept. of Neurosciences, Mental Health, and Sensory Organs, Sapienza University, Rome, Italy
Janja Marc, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Urs A. Meyer, Dept. of Pharmacology, Biocenter of the University of Basel, Basel, Switzerland
Sujit Nair, Pharmaceutical Sciences, University of Mumbai, Mumbai, India
Charity Nofziger, Insitute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria
Ana Peiró, University General Hospital of Alicante, Alicante, Spain
Georgia Ragia, Laboratory of Pharmacology, Democritus University of Thrace, Alexandroupolis, Greece
Jae-Gook Shin, Pharmacogenomics Research Center, Inje University College of Medicine, Busan, South Korea
Maurizio Simmaco, Dept. of Neurosciences, Faculty of Medicine & Psychology, Sapienza University of Rome, Rome, Italy
Sanja Stankovic, Faculty of Biology, University of Belgrade, Belgrade, Serbia
Enrique Terán, School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador
Ron H.N. van Schaik, Dept. of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands
Sophie Visvikis-Siest, INSERM U525, University of Lorraine, Nancy, France

Managing Editor
Ingrid Fricke Galindo
Mexico City, Mexico
E-mail: ingrid_fg@yahoo.com.mx

Editorial Office
Heike Jahnke
Walter de Gruyter GmbH
Genthiner Str. 13, 10785 Berlin, Germany
Tel. +49-30-26005-220; E-mail: heike.jahnke@degruyterbrill.com

Drug Metabolism and Personalized Therapy is covered by the following services:

Baidu Scholar
Cabells Journalytics
CABI (over 50 subsections)
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
EBSCO (relevant databases)
EBSCO Discovery Service
EMBASE
Genamics JournalSeek
Google Scholar
Japan Science and Technology Agency (JST)
J-Gate
JournalGuide
Medline
Naver Academic
Naviga (Softweco)
Norwegian Register for Scientific Journals, Series and Publishers
Primo Central (ExLibris)
ProQuest (relevant databases)
Publons
PubMed
PubsHub
QOAM (Quality Open Access Market)
ReadCube
Reaxys
ScienceON (Korea Institute of Science and Technology Information)
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
TEMA Technik und Management
Text Mining
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Biological Abstracts
Web of Science - BIOSIS Previews
Web of Science - International Pharmaceutical Abstracts
Web of Science - Prous Science Integrity
WorldCat (OCLC)
X-MOL
Yewno Discover

Medicine Clinical Medicine Clinical Medicine, other

Online Submission of Manuscripts

Journal information

Additional information

eISSN:

2363-8915

ISSN:

2363-8907

Language:

English

Publisher:

De Gruyter

Additional information

First published:

December 1, 1980

eISSN: 2363-8915

ISSN: 2363-8907

Audience(s) for this journal

researchers and professionals in the field of pharmacology, basic scientists, translational researchers, industry scientists and professionals in the field of pharmacology

Safety & product resources

Manufacturer information:
Walter de Gruyter GmbH
Genthiner Straße 13
10785 Berlin
productsafety@degruyterbrill.com

Drug Metabolism and Personalized Therapy

Overview

About this journal

Your Benefits

Ahead of Publication / Just Accepted

Issues

Ranking

Submit

Editorial

Abstracting and Indexing

Supplementary Materials

Supplementary Materials

Topics

Topics

External Links

Bibliographic data